Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study

Area of Science:

• Pharmacology
• Critical Care Medicine
• Infectious Diseases

Background:

• Severe nosocomial pneumonia requires effective antibiotic treatment.
• Meropenem is a critical antibiotic for treating serious infections.
• Optimizing meropenem dosing is crucial for critically ill patients.

Purpose of the Study:

• To determine the optimal meropenem treatment regimen for critically ill patients with severe nosocomial pneumonia.
• To evaluate the pharmacokinetic and pharmacodynamic properties of meropenem with different infusion strategies.

Main Methods:

• A study involving 55 critically ill patients with severe nosocomial pneumonia.
• Comparison of intermittent infusion (II) versus extended infusion (EI) of meropenem.
• Pharmacokinetic modeling and Monte Carlo simulations using plasma and epithelial lining fluid (ELF) concentrations.

Main Results:

• Extended infusion (EI) showed a statistically higher penetration ratio into ELF compared to intermittent infusion (II).
• While plasma targets were met, none of the regimens achieved optimal targets in ELF with a 1mg/L breakpoint.
• Only the 2g EI regimen achieved 40%-100% T > 4-fold MIC in plasma.

Conclusions:

• The optimal meropenem regimen for severe nosocomial pneumonia is 2g administered every 8 hours via extended infusion (3 hours).
• This regimen maximizes pharmacodynamic targets in both plasma and epithelial lining fluid.
• This optimized dosing strategy is recommended for critically ill patients to improve treatment outcomes.